Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Chen, Ying Lien ^a,b   Lehman, Virginia N ^a,c   Averette, Anna F ^a   Perfect, John R ^a   Heitman, Joseph ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; CAFKS1 PROTEIN; CASPOFUNGIN; ECHINOCANDIN; FUNGAL PROTEIN; PLACEBO; POSACONAZOLE; TACROLIMUS; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ERGOSTEROL; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS MUTANT; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; ANIMAL; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; SEQUENCE HOMOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; ERGOSTEROL; MALE; MICE; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE HOMOLOGY, NUCLEIC ACID; TACROLIMUS; TRIAZOLES;

EID: 84874613399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057672     Document Type: Article

References (46)

1. Calderone RA (2002) Candida and Candidiasis (Chapter 1: Introduction and historical perspectives): p.3-13. American Society for Microbiology, Washington, DC.
2. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, et al. (2012) Hidden killers: human fungal infections. Sci Transl Med 4: 165rv113.
3. Morrell M, Fraser VJ, Kollef MH, (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640-3645.
4. Dolton MJ, Ray JE, Marriott D, McLachlan AJ, (2012) Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 56: 2806-2813.
5. Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA, (2011) Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report. Int J Antimicrob Agents 38: 540-544.
6. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J, (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418-430.
7. Chen YL, Kozubowski L, Cardenas ME, Heitman J, (2010) On the roles of calcineurin in fungal growth and pathogenesis. Curr Fungal Infect Rep 4: 244-255.
8. Pfaller MA, (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125: S3-13.
9. White TC, Pfaller MA, Rinaldi MG, Smith J, Redding SW, (1997) Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis 3Suppl 1: S102-109.
10. White TC, (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487.
11. Garcia-Effron G, Park S, Perlin DS, (2009) Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53: 112-122.
12. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, (1996) Schooley RT, et al (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335: 1081-1090.
13. Caliendo AM, Hirsch MS, (1994) Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 18: 516-524.
14. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, et al. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333: 1534-1539.
15. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, et al. (2004) Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48: 137-142.
16. Klepser ME, Ernst EJ, Ernst ME, Messer SA, Pfaller MA, (1998) Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother 42: 1387-1391.
17. Odds FC, (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1.
18. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, et al. (2006) Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 50: 2374-2383.
19. Meletiadis J, Pournaras S, Roilides E, Walsh TJ, (2010) Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother 54: 602-609.
20. Worth LJ, Blyth CC, Booth DL, Kong DC, Marriott D, et al. (2008) Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J 38: 521-537.
21. Moerschell RP, Das G, Sherman F, (1991) Transformation of yeast directly with synthetic oligonucleotides. Methods Enzymol 194: 362-369.
22. Moerschell RP, Tsunasawa S, Sherman F, (1988) Transformation of yeast with synthetic oligonucleotides. Proc Natl Acad Sci U S A 85: 524-528.
23. Johnson MD, Perfect JR, (2010) Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 4: 87-95.
24. Onyewu C, Afshari NA, Heitman J, (2006) Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother 50: 3963-3965.
25. Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, et al. (2011) Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother 55: 1543-1548.
26. Chatzimoschou A, Katragkou A, Simitsopoulou M, Antachopoulos C, Georgiadou E, et al. (2011) Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob Agents Chemother 55: 1968-1974.
27. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, et al. (2005) In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 49: 3544-3545.
28. Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, et al. (2006) Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 50: 2587-2590.
29. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, et al. (2002) Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21: 546-559.
30. Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, et al. (1998) Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J Antimicrob Chemother 42: 747-753.
31. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D, (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 44: 2373-2381.
32. Chen YL, Brand A, Morrison EL, Silao FG, Bigol UG, et al. (2011) Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell 10: 803-819.
33. Chen YL, Konieczka JH, Springer DJ, Bowen SE, Zhang J, et al. (2012) Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata. G3 (Bethesda) 2: 675-691.
34. Zhang J, Heitman J, Chen YL, (2012) Comparative analysis of calcineurin signaling between Candida dubliniensis and Candida albicans. Commun Integr Biol 5: 122-126.
35. Zhang J, Silao FG, Bigol UG, Bungay AA, Nicolas MG, et al. (2012) Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. PLoS One 7: e44192.
36. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA, (2003) Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 47: 2373-2375.
37. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, et al. (2006) A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42: 1179-1186.
38. Firinu D, Massidda O, Lorrai MM, Serusi L, Peralta M, et al. (2011) Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole. Clin Dev Immunol 2011 (283239): 1-4.
39. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, et al. (2003) The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 48: 225-235.
40. Dannaoui E, Schwarz P, Lortholary O, (2009) In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 53: 3549-3551.
41. Narreddy S, Manavathu E, Chandrasekar PH, Alangaden GJ, Revankar SG, (2010) In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother 65: 701-703.
42. Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, et al. (2013) Tacrolimus Enhances the Potency of Posaconazole Against Rhizopus oryzae In vitro and In an Experimental Models of Mucormycosis. J Infect Dis.
43. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, et al. (2000) Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 44: 2932-2938.
44. Berge M, Chevalier P, Benammar M, Guillemain R, Amrein C, et al. (2009) Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 31: 396-399.
45. Billaud EM, Guillemain R, Berge M, Amrein C, Lefeuvre S, et al. (2010) Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 48Suppl 1: S52-59.
46. Gillum AM, Tsay EY, Kirsch DR, (1984) Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198: 179-182.